Solid Biosciences Inc. (SLDB): Shareholders' Equity
$180.01M
As of 2025-12-31
$374.07M
As of 2026-06-30
-5.3%
3-year compound annual growth
+6.4%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $180.01M | +31.2% | 2026-03-19, Balance as of period end |
| 2024-12-31 | $137.25M | +8.5% | 2026-03-19, Balance as of period end |
| 2023-12-31 | $126.48M | -40.2% | 2025-03-06, Balance as of period end |
| 2022-12-31 | $211.67M | +1.7% | 2024-03-13, Balance as of period end |
| 2021-12-31 | $208.21M | +57.6% | 2023-03-23, Balance as of period end |
| 2020-12-31 | $132.09M | +65.0% | 2022-03-14, Balance as of period end |
| 2019-12-31 | $80.05M | -36.1% | 2021-03-15, Balance as of period end |
| 2018-12-31 | $125.18M | n/m | 2020-03-12, Balance as of period end |
| 2017-12-31 | -$59.26M | n/a | 2020-03-12, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | 2025-12-31 | $180.01M | +31.2% |
| DBV Technologies S.A. (DBVT) | 2025-12-31 | $168.77M | +516.2% |
| TScan Therapeutics, Inc. (TCRX) | 2025-12-31 | $123.12M | -48.9% |
| Agenus Inc (AGEN) | 2025-12-31 | -$271.11M | n/m |
| Century Therapeutics, Inc. (IPSC) | 2025-12-31 | $158.94M | -1.5% |
| enGene Therapeutics Inc. (ENGN) | 2025-10-31 | $167.71M | -38.5% |
| MeiraGTx Holdings plc (MGTX) | 2025-12-31 | -$5.79M | n/m |
| Metagenomi Therapeutics, Inc. (MGX) | 2025-12-31 | $158.60M | -32.5% |
| Adaptimmune Therapeutics PLC (ADAPY) | 2024-12-31 | $11.85M | -70.0% |
Compare SLDB, DBVT, TCRX, AGEN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗